PAUL EHRLICH-STRASSE 15, TUBINGEN, 2M
Corporate Presentation June 01, 2026
Announces First Quarter 2026 Financial Results and Business Update
Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
PRAME-directed Cell Therapy Using TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Corporate Presentation March 5, 2026
Corporate Presentation January 12, 2026
Corporate Presentation December 11, 2025
Announces $125 Million Underwritten Offering
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus Filed Pursuant to Rule 424(b)(2)
No filings found
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload